Huntington's disease is a fatal human
neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene, which translates into a mutant
huntingtin protein. A key event in the molecular pathogenesis of
Huntington's disease is the proteolytic cleavage of mutant huntingtin, leading to the accumulation of toxic
protein fragments. Mutant huntingtin cleavage has been linked to the overactivation of
proteases due to
mitochondrial dysfunction and
calcium derangements. Here, we investigated the therapeutic potential of
olesoxime, a mitochondria-targeting, neuroprotective compound, in the BACHD rat model of
Huntington's disease. BACHD rats were treated with
olesoxime via the food for 12 months. In vivo analysis covered motor
impairments, cognitive deficits, mood disturbances and brain
atrophy. Ex vivo analyses addressed
olesoxime's effect on mutant huntingtin aggregation and cleavage, as well as brain mitochondria function.
Olesoxime improved cognitive and psychiatric phenotypes, and ameliorated
cortical thinning in the BACHD rat. The treatment reduced cerebral mutant huntingtin aggregates and nuclear accumulation. Further analysis revealed a cortex-specific overactivation of
calpain in untreated BACHD rats. Treated BACHD rats instead showed significantly reduced levels of mutant huntingtin fragments due to the suppression of
calpain-mediated cleavage. In addition,
olesoxime reduced the amount of mutant huntingtin fragments associated with mitochondria, restored a respiration deficit, and enhanced the expression of fusion and outer-
membrane transport proteins. In conclusion, we discovered the
calpain proteolytic system, a key player in
Huntington's disease and other
neurodegenerative disorders, as a target of
olesoxime. Our findings suggest that
olesoxime exerts its beneficial effects by improving mitochondrial function, which results in reduced
calpain activation. The observed alleviation of behavioural and neuropathological phenotypes encourages further investigations on the use of
olesoxime as a therapeutic for
Huntington's disease.